INTRODUCTION {#S2}
============

Following the initial reports of clinical success using chimeric antigen receptor (CAR) T cell therapy to treat B cell leukemia and lymphoma ([@R14]; [@R23]), there have been intense efforts to improve the design and clinical translation of CAR T cells. In addition to T cell receptor (TCR) engagement and costimulatory signaling, cytokines also play a fundamental role in modulating T cell function. Therefore, an appealing strategy is to engineer cytokine production to promote CAR functions, such as interkeulin-12 (IL-12) ([@R3]; [@R22]; [@R29]), IL-15 ([@R11]), and interferon-β (IFN-β) ([@R30]).

We hypothesized that synthetic IL-18 expression might promote CAR T cell functions. IL-18 was initially characterized as an inducer of interferon-γ (IFN-γ) expression in T cells ([@R19], [@R20]) and has been shown to activate lymphocytes and monocytes without eliciting severe dose-limiting toxicity in clinical trials ([@R26]). We previously reported that human recombinant (r)IL-18 could significantly enhance engraftment of human CD8^+^ T cells in a xenograft model ([@R2]). In the current study, we discovered potent IL-18-mediated effects on human and mouse T cell proliferation and that synthetic IL-18 secretion by CAR T cells significantly enhanced CAR T cell expansion and antitumor activity.

RESULTS {#S3}
=======

IL-18 Enhances CAR T Cell Proliferation In Vitro and In Vivo {#S4}
------------------------------------------------------------

To engineer IL-18-expressing CAR T cells, we introduced a human IL-18 transgene into anti-mesothelin (SS1) CAR (SS1-IL-18) and anti-CD19 CAR constructs (CD19-IL-18) ([Figure 1A](#F1){ref-type="fig"}). The resulting SS1-IL-18 construct led to efficient SS1 CAR expression ([Figure S1A](#SD1){ref-type="supplementary-material"}) and secretion of bioactive human IL-18 ([Figures S1B and S1C](#SD1){ref-type="supplementary-material"}) and modestly enhanced the lytic activity of CAR T cells ([Figure S1D](#SD1){ref-type="supplementary-material"}). To evaluate IL-18-CAR T proliferation in vitro, we restimulated CAR T cells with artificial antigen-presenting cells (aAPCs)---K562-expressing mesothelin (K562-Meso) or CD19 (K562-CD19). Robust IL-18 secretion was observed ([Figure S1E](#SD1){ref-type="supplementary-material"}), and IL-18-CAR T cells displayed enhanced secretion of IFN-γ and several other cytokines ([Figure S1F](#SD1){ref-type="supplementary-material"}). Interestingly, SS1-IL-18 CAR T cells displayed significantly increased proliferation relative to SS1 CAR T cells ([Figure 1B](#F1){ref-type="fig"}). However, CD19-IL-18 CAR T cells expanded similarly as the CD19 CAR T cell control ([Figure 1B](#F1){ref-type="fig"}), which is perhaps related to our previous finding that the SS1 CAR has constitutive ligand-independent signaling, whereas the CD19 CAR does not have constitutive signaling ([@R7]).

Encouraged by enhanced functions of IL-18-CAR T cells in vitro, we moved to investigate SS1-IL-18 CAR T cells in a xenograft model of mesothelin-expressing pancreatic tumor AsPC1 (labeled with click beetle green \[CBG\] and GFP reporter proteins) in NOD scid gamma (NSG) mice. Given that AsPC1 cells do not express CD19, we were surprised, 3 weeks after T cell injection, to find that both CD19-IL-18 and SS1-IL-18 T cells were substantially elevated in peripheral blood 62-fold to 13,990 cells/μL or 74-fold to 38,210 cells/μL relative to CD19 or SS1 CAR T alone (p \< 0.01; [Figure 1C](#F1){ref-type="fig"}). We further confirmed the robust T cell expansion when injecting CD19-IL-18 CAR T cells into NSG mice bearing Nalm6 cells, a CD19^+^ leukemia cell line ([Figure 1D](#F1){ref-type="fig"}), and SS1-IL-18 CAR T cells into tumor-free NSG mice ([Figure 1E](#F1){ref-type="fig"}). Further analysis indicated that expanded CD4^+^ and CD8^+^ T cells include both CAR^+^ and CAR^−^ populations in the spleen ([Figures 1F and 1G](#F1){ref-type="fig"}), which were polyclonal ([Figure S1G](#SD1){ref-type="supplementary-material"}). Collectively, these results in the xenograft model suggested that IL-18 promotes target antigen-independent CAR T cell proliferation in vivo in tumor-free and tumor-bearing NSG mice.

Effects of Human IL-18 on T Cell Proliferation and Cytokine Secretion {#S5}
---------------------------------------------------------------------

The observations of CD19-IL-18 CAR T cells proliferating in mice bearing CD19^−^ tumors ([Figure 1C](#F1){ref-type="fig"}) and SS1-IL-18 CAR T cells proliferating in tumor-free mice ([Figure 1E](#F1){ref-type="fig"}) suggest that CAR signaling might be dispensable for IL-18-driven expansion. Therefore, we hypothesized that a functional synergy exists between IL-18 signaling and TCR activation driven by xenogeneic effects. To test this hypothesis in vitro, primary human T cells were stimulated using anti-CD3 only or with rIL-18. Exogenous rIL-18 enhanced increases in T cell volume compared with cells stimulated with anti-CD3 only, and the enhancement in blast transformation after addition of IL-18 was similar to that after addition of anti-CD3/28 beads ([Figure 2A](#F2){ref-type="fig"}). Purified T cells stimulated with anti-CD3 only did not proliferate ([Figure 2A](#F2){ref-type="fig"}); however, anti-CD3 in combination with IL-18 efficiently stimulated proliferation. The costimulatory effect of IL-18 on T cell proliferation was confirmed in T cells isolated from two additional normal donors ([Figure 2B](#F2){ref-type="fig"}).

Further characterization of the cytokine profile in IL-18-activated T cells indicated that low concentrations of IL-18 significantly augmented IFN-γ production, whereas IL-2 levels were at least 20-fold lower than that induced by optimal stimulation by anti-CD3/28 beads ([Figure 2C](#F2){ref-type="fig"}). The production of other cytokines was generally comparable between anti-CD3 plus IL-18 and anti-CD3/CD28 bead activation ([Figure S2A](#SD1){ref-type="supplementary-material"}). Multicolor flow phenotype revealed that IL-18-expanded T cells had a primarily central memory (T~CM~) phenotype (CCR7^+^CD45RO^+^) on day 8 after activation, similar to that obtained with anti-CD3/28 beads ([Figure S2B](#SD1){ref-type="supplementary-material"}).

Combined TCR and IL-18 Signaling Promotes CD4 T Cell Expansion {#S6}
--------------------------------------------------------------

To address the specific roles of T cell subsets in these responses, T cells expanded by standard anti-CD3/CD28 beads were sorted by magnetic-activated cell sorting (MACS) to generate CD4^+^ and CD8^+^ subpopulations. CD8^+^ T cells failed to proliferate after restimulation with rIL-18 and anti-CD3 beads, despite a significant increase in size ([Figure 2D](#F2){ref-type="fig"}), and addition of IL-2 (20 U/mL) had no additional effect. In sharp contrast, CD4^+^ T cells or bulk T cells restimulated with rIL-18 and anti-CD3 beads proliferated efficiently in the absence of CD28 stimulation, at a level comparable with that of combined CD4^+^ and CD8^+^ T cells following anti-CD3/CD28 bead restimulation. rIL-18-re-stimulated CD4^+^ and CD8^+^ T cells displayed transiently elevated T~CM~ markers but ultimately expressed a primarily effector memory (T~EM~) phenotype ([Figure S2C](#SD1){ref-type="supplementary-material"}).

Next, we hypothesized that GFP-IL-18-expressing human T cells would serve as a desirable platform to test the combinatorial effects of IL-18 signaling and TCR xenoreactivity in NSG mice ([Figure 2E](#F2){ref-type="fig"}). GFP-IL-18 CD8^+^ T cells failed to expand in vivo, whereas GFP-IL-18-expressing CD4^+^ or bulk T cells exhibited greater than 400-fold expansion between days 15 and 23 after T cell injection ([Figure 2E](#F2){ref-type="fig"}), which was also associated with massively enlarged spleens. The number of expanded CD4^+^ T cells was comparable whether pure CD4^+^ T cells or total T cells were injected, suggesting that CD8^+^ T cells do not have a significant effect on CD4^+^ T cell expansion ([Figure 2F](#F2){ref-type="fig"}). Interestingly, CD8^+^ T cells proliferated more than CD4^+^ T cells in magnitude within bulk T cells ([Figure 2F](#F2){ref-type="fig"}), which is consistent with our previous finding that rIL-18 only enhanced CD8^+^ T cell engraftment ([@R2]).

Consistent with the observed T cell proliferation, serum human (h)IL-18 and IFN-γ levels increased in mice engrafted with GFP-IL-18 bulk T cells and GFP-IL-18 CD4^+^ T cells but not in mice engrafted with GFP-IL-18 CD8^+^ T cells ([Figure 2G](#F2){ref-type="fig"}). Luminex analysis revealed very high levels of IFN-γ and granulocyte macrophage colony-stimulating factor (GM-CSF) in mice engrafted with IL-18-secreting bulk T cells and IL-18 CD4^+^T cells ([Figure 2H](#F2){ref-type="fig"}). Levels of IP10, MIP-1A, MIP-1B, and tumor necrosis factor alpha (TNF-α) were also selectively elevated in mice engrafted with IL-18 CD4^+^ and IL-18 bulk T cells. IL-17 levels were also selectively elevated in mice engrafted with IL-18 CD4^+^ T cells. In summary, these results suggest that genetically encoded IL-18 acts as a signaling cytokine that interacts synergistically with TCR activation to drive T cell proliferation and Th1-like cytokine secretion, largely dependent on effects through CD4^+^ helper T cells.

TCR and IL-18R Are Required for IL-18-Mediated T Cell Proliferation In Vivo {#S7}
---------------------------------------------------------------------------

Based on the effects of IL-18 in vitro and the dramatic proliferation of GFP-IL-18-expressing T cells in vivo, we hypothesized that both the TCR and IL-18 receptor (IL-18R) are required for IL-18-driven proliferation in vivo. To test this, we engineered TCR-deficient (TCR knockout \[KO\]) T cells expressing GFP or GFP-IL-18 using CRISPR/Cas9 gene editing. TCR^+^ GFP-IL-18 T cells expanded dramatically in the blood and spleen compared with TCR^+^ GFP control T cells, whereas TCR KO GFP-IL-18 T cells did not expand ([Figure 3A](#F3){ref-type="fig"}).

To further investigate the requirement of the IL-18R, we generated IL-18Rα-deficient (IL-18Rα--) T cells using CRISPR/Cas9 gene editing and employed a cell competition assay ([Figure 3B](#F3){ref-type="fig"}) involving CD19 CAR-IL-18 wild-type (WT) cells, GFP WT cells, DsRed TCR KO cells, and AmCyan IL-18R KO T cells. Successful deletion of the TCR and IL-18R was confirmed by flow cytometry, and MACS depletion was performed to remove residual T cells expressing either TCR or IL-18Rα proteins ([Figure 3C](#F3){ref-type="fig"}). Following ex vivo expansion, all four T cell populations were mixed, and flow cytometry analysis confirmed the baseline frequencies of (WT CD19 CAR-IL18):(WT GFP):(TCR KO DsRed):(IL-18R KO AmCyan) cells to be 8.59%:7.45%:6.71%:7.27% within total T cells ([Figure 3D](#F3){ref-type="fig"}). Each NSG mouse received the mixed cell populations consisting of approximately 1e6 cells of each type intravenously. Three weeks later, the number of CD45^+^ human T cells ranged from 32,800 to 79,600 cells/μL blood ([Figure 3E](#F3){ref-type="fig"}), confirming robust T cell proliferation. Staining for IL-18Rα indicated that some AmCyan-labeled T cells had low levels of residual IL-18R expression ([Figure 3F](#F3){ref-type="fig"}), which likely represents contaminating T cells that did not undergo successful gene editing and were not completely removed by MACS depletion.

A representative FACS plot revealed that the final frequencies of (WT CD19 CAR-IL18):(WTGFP):(TCR KO DsRed):(IL-18R KO AmCyan) were 22.0%:18.0%:5.82%:0.43% ([Figure 3G](#F3){ref-type="fig"}). Interestingly, the ratio of WT CD19 CAR-IL-18 to WT GFP T cells following in vivo expansion was essentially unchanged ([Figure 3H](#F3){ref-type="fig"}). In contrast, the proportion of IL-18R KO AmCyan T cells decreased significantly in the blood and spleen, and it was even more dramatic for TCR KO DsRed T cells ([Figure 3H](#F3){ref-type="fig"}). These data indicate that both the TCR and IL-18R are necessary for CAR-IL-18-mediated in vivo proliferation of human T cells and that neither alone is sufficient, as tested in the NSG model.

IL-18 Signaling Significantly Enhances CAR T Cell Proliferation and Antitumor Activity {#S8}
--------------------------------------------------------------------------------------

Given that IL-18 signaling augments TCR signaling, we hypothesized that IL-18 would also augment CAR T cell proliferation because the CAR contains the basic TCR signaling domains. To avoid potential antigen non-specific T cell activation and graft versus host disease (GVHD) associated with endogenous TCR reactivity ([@R15]), only TCR-deficient (TCR KO) human T cells ([@R25]) were used in xenograft experiments. In vitro experiments indicated that TCR KO CD19 CAR and TCR KO SS1 CAR T cells had equivalent proliferation, with or without the IL-18 transgene, after initial activation by anti-CD3/CD28 bead activation and IL-2 ([Figure S3A](#SD1){ref-type="supplementary-material"}). In these experiments, the TCR was disrupted on days 3--4 of culture so that the endogenous TCR was present during the baseline stimulation by anti-CD3/28 beads, and later in culture, the T cells became CD3-deficient (data not shown). However, after aAPC restimulation with the surrogate antigens CD19 or mesothelin, IL-18 expression promoted a modest increase in proliferation in TCR KO CD19-IL-18 CAR T cells ([Figure 4A](#F4){ref-type="fig"}) and SS1-IL-18 CAR T cells ([Figure S3B](#SD1){ref-type="supplementary-material"}). Robust IL-18 secretion was observed during initial ex vivo expansion and after aAPC restimulation ([Figures S3C and S3D](#SD1){ref-type="supplementary-material"}). In addition, TCR KO-IL-18-CAR T cells displayed enhanced secretion of IFN-γ and several other cytokines ([Figure S3E](#SD1){ref-type="supplementary-material"}). Restimulated TCR KO IL-18-CAR T cells displayed transiently elevated T~CM~ markers but ultimately expressed a primarily T~EM~ phenotype ([Figure S3F](#SD1){ref-type="supplementary-material"}).

After confirming enhanced proliferation of TCR KO IL-18-CAR T cells in vitro, we next tested their antitumor activity in NSG mice bearing Nalm6 leukemia cells expressing CBG-GFP. TCR KO CD19-IL-18 CAR T cells effectively cleared detectable tumor cells by day 10, in contrast to TCR KO CD19-GFP CAR T cells ([Figure 4B](#F4){ref-type="fig"}). Notably, control TCR KO SS1-IL-18 CAR T cells had no effect on tumor progression, indicating that IL-18 was not sufficient for the antitumor effect ([Figure 4C](#F4){ref-type="fig"}). NSG mice treated with TCR KO CD19-IL-18 CAR T cells had a transient decrease in body weight on day 8 that returned to baseline levels and remained stable thereafter ([Figure 4C](#F4){ref-type="fig"}), consistent with a transient cytokine release syndrome. Remarkably, mice injected with TCR KO CD19-IL-18 CAR T cells remained viable for over 185 days after T cell injection, except for one mouse that exhibited tumor relapse on day 101 ([Figures 4B and 4C](#F4){ref-type="fig"}) because of downregulation of CD19 expression (data not shown). Additional analysis revealed no emergence of contaminating TCR^+^ CD19-IL-18 CAR T cells during treatment, significant proliferation of TCR KO CD19-IL-18 compared with CD19-GFP CAR T cells (350 versus 10.5 cells/μL blood), a high level of IL-18 in the plasma (77,500 pg/mL on day 10), persistence of CD4^+^ CD19^−^ IL-18 CAR T cells, and a primarily T~EM~ phenotype ([Figure 4C](#F4){ref-type="fig"}). Subsequently, the number of T cells and IL-18 concentrations gradually decreased to below 1 CD45^+^CD3^−^ T cell/μL and approximately 100 pg/mL in tumor-free surviving mice. These results collectively demonstrate that IL-18 can significantly enhance TCR KO CD19 CAR T cell proliferation and induces superior antitumor activity without TCR-mediated GVHD during therapy and that systemic IL-18 levels wane following elimination of the tumor burden.

Although the NSG mice have been the most widely used pre-clinical model of CAR T cell therapy in the study of human T cell adoptive transfer, it would be meaningful to extend the investigation of IL-18-CAR T cells to an immune-competent model. Therefore, we engineered murine IL-18-expressing anti-mouse CD19 (murine CD19-IL-18) CAR T cells for adoptive transfer to C57BL/6 mice bearing B16F10 melanoma tumors stably expressing mouse CD19 ([Figure 4D](#F4){ref-type="fig"}). Murine CD19-IL-18 CAR T cells have superior engraftment in lymphoreplete mice compared with CD19 CAR T cells. In addition, murine CD19-IL-18 CAR T cells had augmented antitumor efficacy, as measured by tumor volume, and significantly enhanced survival. Furthermore, profound B cell aplasia on day 7 after T cell infusion was observed with CD19-IL-18 CAR T cells. Consistent with this, murine CD19-IL-18 CAR T cells resulted in high levels of IL-18 in the plasma on day 7, which decreased rapidly afterward. Consistent with systemic IL-18 levels, mouse body weight decreased slightly on day 7 and then returned to baseline levels. Except for the death of one mouse of 10 mice on day 9, potentially because of systemic IL-18 toxicity, there were no other clinical symptoms observed during the study.

These results indicate that murine CD19-IL-18 CAR T cells have superior on-target effects, as judged by tumor elimination and B cell aplasia, with acceptable toxicity in an immune-competent B16F10 tumor model. Nevertheless, we believe that a safer approach may be to minimize the potential toxicity associated with systemic IL-18 exposure observed in both xenograft and syngeneic models by designing an inducible system for IL-18 CAR T cells. Therefore, we created a nuclear factor of activated T-cells (NFAT)-based inducible system for coupling IL-18 production with CAR signaling along with simultaneous disruption of the endogenous TCR. We designated this approach antigen-propelled activation of cytokine helper ensemble (APACHE) CAR T cells. APACHE CAR T cells have inducible IL-18 secretion upon an encounter with surrogate antigen and enhanced anti-tumor activity in the Nalm6 tumor model ([Figure S4](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#S9}
==========

Except for B cell tumors treated with CD19 CAR T cells, a major limitation of current CAR T cell approaches has been insufficient expansion and persistence of the infused T cells, as exemplified by several trials ([@R1]; [@R8]; [@R12]; [@R16]; [@R21]; [@R24]; [@R27]). IL-18 has been shown to regulate both innate and adaptive immune responses through its effects on natural killer cells, monocytes, dendritic cells, T cells, and B cells ([@R6]). The ultimate rationale for our studies is to enhance CAR T cell proliferation and to utilize IL-18 as a pro-inflammatory cytokine to recruit a second wave of immune cells to the tumor microenvironment to mediate antitumor effects toward cancer cells that are resistant to the direct effects of CAR T cells.

A strength of the NSG xenograft model is that it enables investigation of human IL-18-mediated augmentation of CAR T cell proliferation. There are differences between mouse and human immunology; human T cells are more responsive to IL-18 than mouse T cells. This might help explain why the in vitro effects of human IL-18 on T cells are more potent than those of mouse IL-18 ([@R2]; [@R18]). Because of the immune deficiency of the NSG model and lack of a representative tumor microenvironment, further investigation is underway to comprehensively evaluate the safety of IL-18-CAR T cells, interaction with tumor infiltrating T and natural killer (NK) cells, and modulation of the tumor microenvironment in mice with intact host immune systems.

IL12, a cytokine related to IL-18, has also been shown to augment the functional effects of CAR T cells ([@R4]; [@R22]). Further studies will be required to determine the relative merits and risks of these two approaches. An inducible form of IL-12 was tested in tumor infiltrating lymphocytes (TIL) cells given to melanoma patients and was found to be too toxic ([@R28]). One potential advantage of IL-18 is that it is monomeric, whereas IL-12 is heterodimeric and more susceptible to changes in potency, resulting in lethal toxicity ([@R5]). Many biologic effects of IL-12 and IL-18 are overlapping, so it is unlikely that combining these approaches would be synergistic.

In summary, we demonstrate that CAR T cells can be engineered to secrete IL-18 that supports in vivo engraftment and persistence of CAR T cells. Our observations demonstrate that IL-18 has a previously unappreciated form of signaling that is primarily selective to human CD4^+^ T cells, and, therefore, these IL-18-expressing CD4 T cells can be categorized as synthetic T helper cells producing IL-18 (sTh18). These findings may have therapeutic implications because the IL-18 CAR T cells can support the proliferation of CD8^+^ T cells and because increasing evidence points to the importance of adoptively transferred CD4^+^ T cells in antitumor effects ([@R9]; [@R10]). Finally, our results point to a new approach to develop universal CAR T cells derived from allogeneic T cells that are devoid of the endogenous TCR.

EXPERIMENTAL PROCEDURES {#S10}
=======================

Generation of IL-18-CAR T Cells {#S11}
-------------------------------

All CAR designs are 4-1BB-based second generation. The sequence of human IL-18 (Uniprot: Q14116) and murine IL-18 following a T2A linker were synthesized from Integrated DNA Technologies and Invitrogen. The parental vector pTRPE or MSGV was used to generate the constructs CAR-GFP, CAR-IL-18, GFP, and GFP-IL-18. Human normal donor or murine CD45.1 T cells were ex vivo-expanded by anti-CD3/CD28 beads with exogenous IL-2 and transduced with a lentivector or retroviral vector as reported previously ([@R17]). The generation of an anti-mouse CAR targeting CD19 using the 1D3 rat anti-mouse hybridoma ([@R13]) is described in the [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}. Expression of the anti-mouse CD19 CAR was similar in mouse T cells expressing the CD19 CAR or the CD19-mIL-18 CAR constructs. B16F10 tumor cells expressing mouse CD19 were generated by retroviral transduction and enriched to purity by cell sorting three times for mouse CD19.

Mouse Experiments {#S12}
-----------------

The experiments were conducted under Institutional Animal Care and Use Committee (IACUC)-approved protocol 804226. For syngeneic experiments, the mice were all female, and for experiments with NSG mice, there was a mix of male and female mice. The mice were approximately 8 weeks old at the beginning of each study.

CRISPR/Cas9 Gene Disruption {#S13}
---------------------------

Primary donor T cells were engineered with CRISPR/Cas9 as reported previously ([@R25]). TCR-deficient T cells were achieved with single guide RNA (sgRNA) targeting GGAGAATGACGAGTGGACCC within the TCRB region. For the IL-18R knockout, we identified an sgRNA targeting IL-18Rα (GTACAAAAGCAGTGGATCAC) with high efficiency.

More details are available in the [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}.
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![IL18-CAR T Cells Have Enhanced Proliferation In Vitro and In Vivo\
(A) The construct designs.\
(B) Population doubling and cell volume of SS1 anti-mesothelin or anti-CD19 CAR T cells following the first restimulation with irradiated K562-Meso or K562-CD19 with exogenous IL-2.\
(C) NSG mice (n = 5) bearing an AsPC1 pancreatic flank tumor received CD19 or SS1 CAR T cells (2e6), and 3 weeks later, peripheral blood was analyzed by Trucount.\
(D) NSG mice (n = 5) bearing a systemic Nalm6 acute lymphoblastic leukemia (ALL) tumor received 1e6 CD19 or CD19-IL-18 CAR T cells. After 18 days, circulating T cells were assessed.\
(E) Tumor-free NSG mice (n = 5) were inoculated with 5e6 SS1 or SS1-IL-18 CAR T cells and, 3 weeks later, analyzed for circulating T cells.\
(F and G) CAR T cells were analyzed on day 9 of ex vivo expansion. In vivo expansion of SS1-IL-18 and CD19-IL-18 CAR T cells was determined by harvesting spleens from the mice described in (C) and (D), respectively.\
(F) Representative fluorescence-activated cell sorting (FACS) plots of CD8^+^CAR^+^ cells.\
(G) The percentage of CD4^+^CAR^+^ or CD8^+^CAR^+^ T cells in spleens from (F).\
All data with error bars are presented as mean ± SEM. Student's t test: \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms958793f1){#F1}

![Combined TCR and IL-18 Signaling Promotes CD4^+^ T Cell Expansion in the Absence of CAR Signaling\
(A--C) Primary T cells from a healthy donor were activated with anti-CD3 beads and varying concentrations (1.56 doubled up to 200 ng/mL) of rIL-18 added on days 0 and 3.\
(A) Changes in T cell volume and cell numbers.\
(B) IL-18-dependent expansion of T cells from two additional donors stimulated with rIL-18, anti-CD3 beads, and anti-CD3 beads plus rIL-18.\
(C) Luminex analysis of secreted IFN-γ and IL-2 with 12 culture conditions indicated. Additional cytokine data are shown in [Figure S2A](#SD1){ref-type="supplementary-material"}.\
(D) Normal donor T cells expanded with anti-CD3/CD28 beads for 10 days were selected by MACS columns to purify CD8^+^ and CD4^+^ T cells. Purified CD4^+^ T cells, CD8^+^T cells, or bulk T cells were restimulated with anti-CD3 beads and 100 ng/mL rIL-18, added on days 0 and 3, as indicated in the legend.\
(E--H) T cells transduced with lentivectors encoding GFP orGFP-IL-18 were selected using MACS columns to purify CD8^+^ and CD4^+^ T cells. Tumor-free NSG mice (n = 5) were injected with 2e6 T cells as indicated. The data shown are representative of two independent experiments.\
(E) Circulating CD45^+^ T cells and pictures of spleens from various groups.\
(F) Circulating CD45^+^CD4^+^ T cells on day 23 following T cell injection and the ratio of CD8^+^ to CD4^+^ T cells.\
(G) Serum levels of IL-18 and IFN-γ.\
(H) Serum from mice on day 23 was analyzed by Luminex to assess the cytokine profile.\
All data with error bars are presented as mean ± SEM. Student's t test: \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms958793f2){#F2}

![IL-18-Enhanced T Cell Proliferation Requires TCR and IL-18R Signaling\
(A) Tumor-free NSG mice (n = 5) were injected with 2e6 TCR KO or TCR WT GFP-IL-18 T cells or the indicated controls. After 18 days, T cells in the blood (top) or spleens (bottom) were assessed.\
(B) Cell-competitive repopulation design. CD19 CAR-IL-18 WT, GFP WT, AmCyan IL-18R KO and DsRed TCR KO T cells were mixed together and injected into tumor-free NSG mice (n = 5).\
(C) Purity of TCR KO and IL-18R KO cells after CRISPR/Cas9 gene editing and MACS sorting.\
(D) Initial frequency of each cell population shown in (B).\
(E--H) The mice were analyzed 3 weeks after T cell injection.\
(E) Left: total circulating CD45^+^ cells, indicating robust expansion. Right: individual populations of T cells.\
(F) Expression levels of IL-18Rα on T cells in the blood (left) and spleen (right).\
(G) Representative FACS plot of each cell population in the blood.\
(H) The ratios of CD19 CAR-IL-18 WT, IL-18R KO AmCyan, and TCR KO DsRed to GFP WT cells in the blood (left) and spleen (right).\
All data with error bars are presented as mean ± SEM. Student's t test: \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms958793f3){#F3}

![IL-18 Costimulation Significantly Enhances Proliferation and Antitumor Activity of Human TCR-Deficient and Syngeneic Murine CD19 CAR T Cells\
(A) Expansion kinetics and volume of TCR KO CAR T cells following the first (with IL-2) and second (without IL-2) restimulation with irradiated K562-CD19cells.\
(B and C) NSG mice were injected intravenously with 1e6 Nalm6 ALL cells expressing CBG-GFP. On day 7 after tumor injection, mice (n = 5) received the indicated TCR KO CAR T cells (1e6). The data shown are representative of two independent experiments.\
(B) Live animal imaging of tumor growth.\
(C) Tumor growth curves of four groups (left) and a magnified plot of TCR KO CD19-GFP and TCR KOCD19-IL-18 CAR T cohorts (right). Additional data include body weight, survival, number of CD45^+^CD3 KO T cells, IL-18 plasma concentration, percentage of CD3 KO cells among total CD45^+^ cells, distribution of CD4^+^ and CD8^+^ T cells within CD19 CAR T cells, and memory phenotype in CD4^+^ and CD8^+^ CAR T cells.\
(D) Study of murine CD19-IL-18 CAR T cells in the B16F10 melanoma tumor model that was derived from the B6 mouse in 1954. Lymphocyte-replete C57BL/6 (CD45.2 strain) mice were inoculated subcutaneously (s.c.) with 2e6 B16F10 tumor cells expressing murine CD19 (B16-mCD19). One week later, mice were randomized and treated with 5e6 murine CD19-GFP (n = 10) or CD19-IL18 (n = 10) CAR T cells (CD45.1 origin) or left untreated (n = 7). The mice were monitored for tumor growth, B cell frequency, survival, body weight, CD45.1 T cells, and murine IL-18 plasma concentration.\
All data with error bars are presented as mean ± SEM. In some cases, the magnitude of the SEM is less that the size of the symbol. Student's t test: \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms958793f4){#F4}

###### Highlights

-   Augmented proliferation of synthetic IL-18-expressing human T cells

-   rIL-18 augments IFN-γ secretion and proliferation of anti-CD3 activated T cells

-   IL-18-secreting CD4^+^ T cells promote CD8^+^ T cells through a helper effect

-   IL-18 CAR T cells have superior proliferation and antitumor activity in mouse models
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